COVID-19 Vaccines in Oncology Patients
Dr. Peter Anglin, Dr. John Kuruvilla, Dr. Coleman Rotstein
Dr. John Kuruvilla – Princess Margaret Cancer Centre
Dr. John Kuruvilla is an Associate Professor of Medicine at the University of Toronto and a Clinical Investigator in the Division of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto. He is a hematologist and member of the Lymphoma Program and the Autologous Blood and Marrow Transplant program. Dr. Kuruvilla’s research interest is the development of novel therapeutics in lymphoid malignancies and incorporating translational research into clinical trials. He is the Lymphoma Co-Chair for the Canadian Cancer Trials Group (CCTG) as well as the Chair of the Scientific Advisory Board of Lymphoma Canada.
Dr. Peter Anglin – Stronach Regional Cancer Centre
Dr. Peter Anglin obtained his medical degree from Queen’s University at Kingston and followed this with clinical fellowships in internal medicine, hematology and oncology. He has been in clinical practice for the last 21 years in the Greater Toronto Area and is currently a staff Hematologist/Medical Oncologist and Physician Lead at the Stronach Regional Cancer Centre at Southlake Health in Newmarket, Ontario. Dr. Anglin’s clinical focus has been in hematologic and lymphoid malignancies. After pursuing an MBA from the Rotman School of Management (University of Toronto) he has developed an interest in health systems delivery and process redesign in the clinical ambulatory setting.
Dr. Coleman Rotstein – University Health Network
Dr. Rotstein is Professor of Medicine in the Division of Infectious Diseases at the University of Toronto and Attending Physician at the University Health Network, Toronto, Ontario. He received a Bachelor of Science at the University of Toronto and earned his medical degree from the University of Calgary in 1976. Dr. Rotstein completed his specialty training in Internal Medicine at the University of Toronto and pursued further subspecialty training in Infectious Diseases & Immunology at the Medical University of South Carolina in Charleston, South Carolina from 1980 to 1983 [ABIM (1980), FRCPC (Internal Medicine 1981), Infectious Diseases ABIM (1982)]. Dr. Rotstein is currently the Director of Oncologic Infectious Diseases of the Immunocompromised Host Infectious Diseases Service at the University Health Network. He serves on the Board of the Canadian Foundation for Diseases and is the Chair of the Awards Committee of the Foundation. Dr. Rotstein is also a member of the National Advisory Committee on Immunization of the Public Health Agency of Canada. In addition, he has been elected a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is also a fellow of the European Confederation of Medical Mycology. He functions as a reviewer for several international journals. Dr. Rotstein has published over 190 peer-reviewed papers. His research interests have focused mainly on infections in cancer patients and other immunocompromised hosts as well as fungal infections caused by Candida organisms. He maintains active research interests in immunocompromised hosts.